**Influenza (LAIV).** (NACI Statement 2016)

- **Indications**
  - Seniors ≥ 65 years old
  - All children ≥ 6 months of age
  - PCH residents
  - Anyone with chronic health issues
  - Health care workers & first responders
  - Pregnant women
  - Morbidly obese people
  - Aboriginal peoples
  - Household contacts of those listed above

- **Contraindications to Flu Vaccine**
  - History of anaphylaxis to a previous flu vaccination
  - History of Guillain-Barre syndrome within 6 weeks of a previous flu vaccination
  - Infants < 6 months of age
  - History of anaphylaxis to any vaccine component listed in the following product:
    - Fluzone® vaccine: egg protein*, formaldehyde, Triton® X-100, sucrose, thimerosal (multidose presentation only). Fluzone® is latex-free
    - Flulaval® vaccine: Egg protein*, sodium deoxycholate, ethanol, formaldehyde, sucrose, α-tocopheryl hydrogen succinate, polysorbate 80, thimerosal (multidose presentation only).
    - (FluMist® vaccine: see reverse side)

- **Vaccine Dose**
  - **Age group**
    - 6 months to < 9 years: 0.5 mL
    - ≥ 9 years: 0.5 mL
  - **# of doses**
    - 1 or 2**
  - **Route**
    - IM

*NACI has concluded that egg allergic individuals may be vaccinated against influenza using inactivated...QIV without prior influenza vaccine skin test and with the full dose. The vaccine may be given in any setting where vaccines are routinely administered. Clients should be observed for 30 minutes post vaccination. Live attenuated influenza vaccine (LAIV) (FluMist®) should NOT be given to egg allergic individuals as egg allergy has not yet been studied for (LAIV).” (NACI Statement 2016-2017).

** Two doses administered at least one month apart are recommended for children < 9 years of age receiving seasonal influenza vaccine for the first time.

---

**Pneumococcal 23 Vaccine 2016**

- **Indications**
  - All seniors ≥ 65 years of age
  - All residents of PCHs
  - All persons ≥ 2 years of age with:
    - Chronic heart or lung disease (except asthma)
    - Chronic kidney or liver disease, cancer, diabetes
    - Weakened immune system r/t disease or therapy
    - Anatomic or functional asplenia r/t sickle cell disease, inflammatory bowel disease, celiac disease, thalassemia, lupus, or low platelet levels

- **Contraindications to Pneumovax 23® Vaccine**
  - History of anaphylaxis to a previous dose of a pneumococcal vaccine
  - Pneumovax 23® vaccine: history of anaphylaxis to any component of Pneumovax 23 (ie/ phenol)
  - Do not administer Pneumovax23 and ZOSTAVAX™ vaccine at the same time due to the possibility of an inferior immune response to ZOSTAVAX™. Separate these vaccines by 4 weeks.
  - The container closure system of Pneumovax 23 is latex-free.

- **Common side effects**
  - Injection site reactions such as pain, tenderness, redness, swelling.
  - Systemic reactions such as fatigue, sore muscles, headache.

**Dosage for Adults and Children ≥ 2 years of age: 1 dose 0.5 mL IM or SC**

**Routine re-immunization of healthy individuals with Pneu-P-23 vaccine is not recommended.** However, one lifetime booster is recommended 5 years after the initial dose for those at highest risk of invasive pneumococcal disease (ie/ asplenia, sickle cell disease, liver or kidney disease, HIV infection and immunosuppression). Because there are insufficient data to recommend repeated administration of Pneu-P-23 vaccine, re-vaccination following a second dose is not routinely recommended. (CIG 2013). The public health program follows the provincial & national guidelines & will not be administering more doses than currently recommended.
Indications:
- 2 – 17 years of age

Contraindications:
- Children < 2 years of age
- Pregnant females
- Children with an immune system weakened by disease or medical treatment
- History of severe allergic (anaphylactic) reaction to a previous dose of any type of flu vaccine or any component of FluMist® (egg protein, gentamycin [tobramycin, neomycin, streptomycin, kanamycin, amikacin], gelatin hydrolysate, sucrose, arginine, monosodium glutamate)
- Those with an allergy to eggs
- Those with severe asthma or active wheezing in the last 7 days
- Health care workers working with immunocompromised individuals.
- Those ≤ 17 years of age who are on long term aspirin treatment in the last 4 weeks
- Those with a history of Guillain Barre Syndrome (GBS) within 6 weeks of receipt of a previous dose of flu vaccine without another cause being identified.

Common side effects:
- May cause mild influenza symptoms including runny nose, nasal congestion, cough, sore throat, fever.
- Some children may have a headache, decreased appetite or weakness

Dosage:
- FluMist is administered via the intranasal (ITN) route. The dosage is 0.2 mL (0.1 mL in each nostril).
- Children 9 years of age and older need 1 dose of vaccine.
- Children 2 to 8 years of age who have never received a seasonal influenza vaccine need 2 doses administered at least one month apart.